Learn more about how Cytobank’s new advanced viSNE (t-SNE) settings automate and improve analysis of large cytometry datasets with precision. More »
Cytobank has released version 5.5.0 with enhancements to our API, enabling more flexible and functional workflows that leverage Cytobank’s secure infrastructure and cloud-based compute and storage. Among the enhancements are new API endpoints for viSNE, CITRUS, SPADE, sharing, Sample Tags, and compensation.
At Cytobank, we’ve seen emerging needs among scientists and research organizations the world over that are driving the development of our API. These needs often demand functionality beyond that given by basic browser-based analysis sessions, with themes including connecting the Cytobank platform directly to other information systems, allowing batch processing and chaining of native functionality, and supporting pull and push of data, configurations, statistics, and attachments from Cytobank to support external pipelines, algorithms, and studies.
In this article, we present a variety of workflows highlighting how the Cytobank API can increase the efficiency and velocity of research efforts. Illustrated workflows include:
Leaders in the field are utilizing the Cytobank Platform to discover more and are presenting these findings at American Society of Hematology’s 2016 Meeting this weekend, one of the most important clinical meetings world wide, driven by explosive growth in immunotherapy related research.
Take advantage of the scalable compute available in the cloud with our latest enhancements to viSNE. Now Cytobank’s cloud-hosted platform can run up to 20x more events than other locally-run solutions. Fully optimize the resolution of your results by fine-tuning Iterations, Perplexity, and Theta. More »
Last Call: Register for Our CITRUS Webinar Oct 19.
Only hours remain to register for our CITRUS webinar. Don’t miss out! Join us Wednesday, October 19th at 9AM PDT for CITRUS: Applications and Insights from the Experts.
Learn more about how Cytobank’s newest tool can help you automate and accelerate biomarker discovery. Hear from our team members and a panel of experts:
- Our Cytobank scientists will review how to get started quickly with CITRUS in Cytobank with a live demo.
- Gabi Fragiadakis, Ph.D., will share practical applications and show how she used CITRUS to find biomarkers of clinical recovery in surgery patients.
- CITRUS algorithm creator, Rob Bruggner, Ph.D., will answer your questions during a live Q&A session.
Automatically Identify Predictive Biomarkers with Our Newest Algorithm
Why do some cancer patients respond well to immunotherapy but others do not?
Why do some people have a slow and painful recovery from surgery but others have a speedy recovery?
What are the biomarkers that can help predict these outcomes ahead of time?
High-dimensional single-cell analysis approaches are excellent for investigating such questions because many mechanisms of disease may only be visible at the single-cell level, eluding bulk analysis techniques. Emerging technologies such as high parameter fluorescence and mass cytometry, and powerful data analysis platforms like Cytobank, are providing unprecedented resolution for measuring single-cell biology. With these new technologies, a variety of specific cellular populations can be simultaneously identified, and anomalies can define different clinically relevant cohorts and serve as predictive diagnostics and prognostics.
The challenge of going from high-dimensional data to these useful findings lies in the analysis, which is often cumbersome, manual, subjective, and irreproducible. Our new version of the CITRUS algorithm aims to change that. More »
Welcome to Cytobank User Stories, a series featuring interviews with Cytobank users on their research, scientific vision, and use of fluorescence and mass cytometry.
This week we interview Reema Baskar, a graduate student in the Cancer Biology Department at Stanford University, co-mentored by Sean Bendall and Sylvia Plevritis. We asked Reema about how she uses Cytobank’s high-dimensional tools to help elucidate mechanisms of drug resistance in cancer, and her early experience beta-testing our new CITRUS implementation.
|What is an important problem in human health and/or fundamental biology that you’d like to address? What is your scientific vision?|
My vision is to develop high-dimensional techniques and computational tools to address the challenge of ‘big data.’ My hope is that these tools may be broadly applied to aid our understanding of the human condition. Technology, such as mass cytometry (CyTOF), has made it possible to capture different facets of biology such as cell function, epigenetic traits, and transcriptional readouts with infinitesimal single-cell granularity. More »